MAXVAX Biotechnology Limited Liability Company
Chengdu, Sichuan Sheng, China
Purpose
To evaluate the MA107 adjuvant as a candidate for use in scalable and affordable vaccines that support global health immunization effort.
Division
Global Health
Date
October 2025
Region Served
GLOBAL
Committed amount
$554,163
Grant topic
Discovery and Translational Sciences
Duration (months)
14
Grantee location
Chengdu, Sichuan Sheng, China
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.